Medtentia International and clinicalprojects international Tap BioClinica for Express EDC, Data Management, and Centralized

  Medtentia International and clinicalprojects international Tap BioClinica
  for Express EDC, Data Management, and Centralized Imaging Reads

International Experience, Flexibility, and Speed to Support Innovative Cardiac
                               Device Research

Business Wire

NEWTOWN, Pa. -- March 4, 2013

BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial
management solutions, today announced an agreement for BioClinica Express EDC,
data management, and imaging core lab services with Finnish company Medtentia
International, in partnership with the contract research organization (CRO)
clinicalprojects international (CPI). Medtentia International Ltd. is a
medical technology company which develops solutions for mitral valve repair
based on its proprietary helix ring concept. Medtentia’s technology has the
potential to reduce the invasiveness, operation time and morbidity associated
with mitral valve repair operations.

Medtentia is the latest European customer to select BioClinica eClinical and
Imaging Core Lab offerings. BioClinica services will support Medtentia’s
multi-country, multi-year study of a medical device for mitral valve (heart)
repair. "We awarded this clinical trial to CPI and BioClinica based on the
excellent feedback we received from their reference clients,” commented Olli
Keranen, CEO of Medtentia. “We were already familiar with BioClinica’s Imaging
Core Lab solutions and wanted to outsource EDC and DM to a stable global
eClinical vendor. We are confident that both companies’ reputations for
customer focus and respective strengths will well serve the needs of an
innovative medical device company like Medtentia."

Based in Bonn, Germany, CPI is focused on the planning and execution of Phase
I-IV as well as post-marketing studies for innovative medical devices,
combination products and (Bio)Pharmaceuticals. “We are delighted that
Medtentia has entrusted us with their trial and look forward to another
successful collaboration with the BioClinica team,” said Jörg Breitkopf,
Managing Director of CPI. “BioClinica has a strong service and technology
reputation among medical device companies. Our partnership will provide
Medtentia with the utmost in clinical trial support.”

"BioClinica’s fresh and more cost-efficient approach to clinical trial support
is currently driving unprecedented sponsor and CRO partnership growth across
both eClinical and Imaging Core Labs solutions,” said Mark Weinstein, CEO of
BioClinica. We continue to expand our team, especially in Europe, adding to
our experience and global reach, and are pleased to have been selected to help
support this important cardiac device research.”

Follow BioClinica on the Trial Blazers blog at, and on twitter at

About Medtentia International Ltd Oy

Medtentia International Ltd Oy is a clinical-stage medical technology company
developing novel mitral valve therapy products based on the company’s
proprietary helix technology. The company, based in Helsinki, Finland, is
backed by leading Nordic venture capital funds. Additional company information
can be found at

About CPI

clinicalprojects international GmbH provides professional CRO services for
manufacturers of medical devices, combination products and biopharmaceuticals.
Since CPI’s foundation in 2007, clients have turned to it for a range of
clinical research support from the completion of individual tasks to
full-project outsourcing. CPI has been involved in numerous medical device
studies in various indications, most recently in cardiology, neuromodulation
and pain. See more at

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management solutions. BioClinica supports
pharmaceutical and medical device innovation with imaging core lab, internet
image transport, electronic data capture, interactive voice and web response,
clinical trial management and clinical supply chain design and optimization
solutions. BioClinica solutions maximize efficiency and manageability
throughout all phases of the clinical trial process. With over 22 years of
experience and more than 2,500 successful trials to date, BioClinica has
supported the clinical development of many new medicines from early phase
trials through final approval. BioClinica operates state-of-the-art,
regulatory-body-compliant imaging core labs on two continents, and supports
worldwide eClinical and data management services from offices in the United
States, Europe and Asia. For more information, please visit

Certain matters discussed in this press release are “forward-looking
statements” intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995. In
particular, the Company’s statements regarding trends in the marketplace and
potential future results are examples of such forward-looking statements. The
forward-looking statements contained in this press release are based on our
current expectations, and those made at other times will be based on our
expectations when the statements are made. The forward-looking statements
include risks and uncertainties, including, but not limited to, the
consummation and the successful integration of current and proposed
acquisitions, the timing of projects due to the variability in size, scope and
duration of projects, estimates and guidance made by management with respect
to the Company’s financial results, the demand for our services and
technologies, growing recognition for the use of independent medical image
review services, trends toward the outsourcing of imaging services in clinical
trials, realized return from our marketing efforts, increased use of digital
medical images in clinical trials, expansion into new business segments,
backlog, critical accounting policies, regulatory delays, clinical study
results which lead to reductions or cancellations of projects, and other
factors, including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein and expressed
from time to time in the Company’s filings with the Securities and Exchange
Commission could cause actual results and developments to be materially
different from those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press release
and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstance. You
should review the Company’s filings, especially risk factors contained in the
Form 10-K and the recent Form 10-Q.


BioClinica, Inc.
Company Contact - Jim Dorsey
Diccicco Battista Communications
Trade Media – Morgan Dub Karpo
Porter, LeVay & Rose, Inc.
Investor Contact - Michael Porter
Financial Media - Bill Gordon
Press spacebar to pause and continue. Press esc to stop.